21st Annual The Irwin D. Mandel Advances in Cardiovascular Risk Reduction: Optimizing Therapies for Cardiometabolic Health

NYU Langone Health, 550 First Ave
New York, NY
United States
December 4, 2025 7:30 AM – 5:00 PM

This one-day course will cover state-of-the-art management of patients with cardiovascular risk factors. The course will highlight evidence-based recommendations for the management of patients with cardiovascular risk factors including those with co-morbidities such as diabetes, hypertension, obesity and heart failure. A special research presentation on obesity, fat and lipid homeostasis will highlight important ongoing research in the overlap between obesity and cardiovascular disease. The course will provide updates on the role of revascularization, highlighting the ongoing ISCHEMIA trial. Select presentations will take a deep dive into the importance of SGLT2 and PSCK9 inhibitors in treating cardiovascular risk in patients with or without diabetes. Future therapies targeting biomarkers such as lipoprotein (a) will be discussed, including newly approved therapies targeting ApoC3 in Familial Chylomicronemia Syndrome (FCS) and ANGPTL3 in homozygous familial hypercholesterolemia (HoFH). Participants will also be updated on non-invasive imaging plaque imaging techniques.

Attendees will participate in an hour-long case conference with challenging cases in cardiovascular disease risk reduction from a preventive cardiology clinic. The course includes morning and afternoon panel discussion segments including an audience question and answer time.

This course is designed to provide an informative and practical guide towards the clinical management of cardiovascular risk factors. This course is designed to bolster the clinician’s approach to prevent, diagnose and treat cardiovascular risk factors.

This course will be live-streamed and offered in-person.

Jointly provided by the NYU Grossman School of Medicine and the New York Chapter American College of Physicians.

Organized by the Center for the Prevention of Cardiovascular Disease, the Division of Cardiology, and the Division of Endocrinology, Diabetes and Metabolism